Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Central Serous Chorioretinopathy
NCT01822561Phase 2Completed
- Sponsor
- Tufts Medical Center
- Start
- May 2013
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eplerenone in Central Serous Chorioretinopathy (CSCR), sponsored by Tufts Medical Center. Primary endpoint: Complete Resolution of Subretinal Fluid at 1 month. Started May 2013; status: completed.
02
Drugs
eplerenone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT01822561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822561.